Adrenocortical carcinomas (ACC) are rare tumours responsible for only 0.02% of the total number of malignant diseases. However the ACC are aggressive with a mean fiveyears survival of 20-50% and are often associated with increased production of adrenocortical hormones. The effect of the treatment is controversial and often based on small retrospective series or expert opinions. Centralization, international attention and collaboration in the treatment of ACC are mandatory. Randomized clinical trials are needed to determine the best treatment strategy in order to increase survival in patients with ACC.
|Translated title of the contribution||Treatment of adrenocortical carcinomas is challenging|
|Journal||Ugeskrift for Laeger|
|Number of pages||5|
|Publication status||Published - 22 Apr 2013|